miR-22 inhibits osteosarcoma cell proliferation and migration by targeting HMGB1 and inhibiting HMGB1-mediated autophagy

Tumor Biology

Volumn 35, Issue 7, 2014, Pages 7025-7034

  Guo, Shibing ^a   Bai, Rui ^a   Liu, Wanlin ^a   Zhao, Aiqing ^b   Zhao, Zhenqun ^a   Wang, Yuxin ^a   Wang, Yong ^a   Zhao, Wei ^a   Wang, Wenxuan ^a  

^a INNER MONGOLIA MEDICAL UNIVERSITY   (China)

^b INNER MONGOLIA MEDICAL UNIVERSITY   (China)

Author keywords

HMGB1; Migration; miR 22; Osteosarcoma; Proliferation

Indexed keywords

CISPLATIN; DOXORUBICIN; HIGH MOBILITY GROUP B1 PROTEIN; MESSENGER RNA; MICRORNA 22; RAPAMYCIN;

3' UNTRANSLATED REGION; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; AUTOPHAGY; CANCER CHEMOTHERAPY; CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE CONTROL; HUMAN; HUMAN CELL; IN VITRO STUDY; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

3' UNTRANSLATED REGIONS; AUTOPHAGY; BONE NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HMGB1 PROTEIN; HUMANS; MICRORNAS; OSTEOSARCOMA;

EID: 84904994903     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1965-2     Document Type: Article

References (45)

1. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3-13.
2. Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol Off J Am Soc Clin Oncol. 1997;15:76-84. (Pubitemid 27020560)
3. Goorin AM, Schwartzentruber DJ, Devidas M, Gebhardt MC, Ayala AG, Harris MB, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21:1574-80. (Pubitemid 46594112)
4. Wittig JC, Bickels J, Priebat D, Jelinek J, Kellar-Graney K, Shmookler B, et al. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician. 2002;65:1123-32.
5. Rosen G, Caparros B, Groshen S, Nirenberg A, Cacavio A, Marcove RC, et al. Primary osteogenic sarcoma of the femur: a model for the use of preoperative chemotherapy in high risk malignant tumors. Cancer Investig. 1984;2:181-92. (Pubitemid 14079557)
6. White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15:5308-16.
7. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer. 2007;7:961-7. (Pubitemid 350165856)
8. Livesey KM, Tang D, Zeh HJ, Lotze MT. Autophagy inhibition in combination cancer treatment. Curr Opin Investig Drugs. 2009;10:1269-79.
9. LotzeMT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5:331-42. (Pubitemid 40516158)
10. Tang D, Kang R, Zeh 3rd HJ, LotzeMT. High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal. 2011;14:1315-35.
11. Tang D, Kang R, Zeh 3rd HJ, Lotze MT. High-mobility group box 1 and cancer. Biochim Biophys Acta. 2010;1799:131-40.
12. Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, et al. Endogenous HMGB1 regulates autophagy. J Cell Biol. 2010;190:881-92.
13. Tang D, Kang R, Livesey KM, Kroemer G, Billiar TR, Van Houten B, et al. High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab. 2011;13:701-11.
14. Liu L, Yang M, Kang R, Wang Z, Zhao Y, Yu Y, et al. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia. 2011;25:23-31.
15. Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE, et al.HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene. 2010;29:5299-310.
16. Huang J, Ni J, Liu K, Yu Y, XieM, Kang R, et al. HMGB1 promotes drug resistance in osteosarcoma. Cancer Res. 2012;72:230-8.
17. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell. 2003;113:673-6. (Pubitemid 36724931)
18. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215-33.
19. Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM. Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in drosophila. Cell. 2003;113:25-36. (Pubitemid 36411957)
20. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000;403:901-6. (Pubitemid 30130993)
21. Zou Z, Wu L, Ding H, Wang Y, Zhang Y, Chen X, et al. MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy. J Biol Chem. 2012;287:4148-56.
22. Hu H, Li S, Cui X, Lv X, Jiao Y, Yu F, et al. The overexpression of hypomethylated miR-663 induces chemotherapy resistance in human breast cancer cells by targeting heparin sulfate proteoglycan 2 (HSPG2). J Biol Chem. 2013;288:10973-85.
23. Bourguignon LY, Wong G, Earle C, Chen L. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem. 2012;287:32800-24.
24. Kastl L, Brown I, Schofield AC. miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat. 2012;131:445-54.
25. Tao J, Lu Q, Wu D, Li P, Xu B, Qing W, et al. MicroRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells. Oncol Rep. 2011;25:1721-9.
26. Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene. 2009;28:4065-74.
27. Mukhopadhyay P, Pacher P, Das DK. MicroRNA signatures of resveratrol in the ischemic heart. Ann N Y Acad Sci. 2011;1215:109-16.
28. Zhu H, Wu H, Liu X, Li B, Chen Y, Ren X, et al. Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells. Autophagy. 2009;5:816-23.
29. Brest P, Lapaquette P, Souidi M, Lebrigand K, Cesaro A, Vouret-Craviari V, et al. A synonymous variant in IRGMalters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease. Nat Genet. 2011;43:242-5.
30. Xiao J, Zhu X, He B, Zhang Y, Kang B, Wang Z. Ni X. miR-204 regulates cardiomyocyte autophagy induced by ischemia-reperfusion through LC3-II. J Biomed Sci. 2011;18:35.
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta c(t)) method. Methods. 2001;25:402-8. (Pubitemid 34164012)
32. Kim SW, Li Z, Moore PS, Monaghan AP, Chang Y, Nichols M, et al. A sensitive non-radioactive Northern blot method to detect small RNAs. Nucleic Acids Res. 2010;38:e98.
33. Polioudakis D, Bhinge AA, Killion PJ, Lee BK, Abell NS, Iyer VR. A Myc-microRNA network promotes exit from quiescence by suppressing the interferon response and cell-cycle arrest genes. Nucleic Acids Res. 2013;41:2239-54.
34. Paglin S, Hollister T, Delohery T, Hackett N, McMahill M, Sphicas E, et al. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res. 2001;61:439-44. (Pubitemid 32128593)
35. Dai Z, Barbacioru C, Huang Y, Sadee W. Prediction of anticancer drug potency from expression of genes involved in growth factor signaling. Pharm Res. 2006;23:336-49. (Pubitemid 43237864)
36. Dai Z, Huang Y, Sadee W. Growth factor signaling and resistance to cancer chemotherapy. Curr Top Med Chem. 2004;4:1347-56. (Pubitemid 39242877)
37. Dai Z, Huang Y, Sadee W, Blower P. Chemoinformatics analysis identifies cytotoxic compounds susceptible to chemoresistance mediated by glutathione and cystine/glutamate transport system xc. J Med Chem. 2007;50:1896-906. (Pubitemid 46626599)
38. Huang Y, Dai Z, Barbacioru C, Sadee W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res. 2005;65:7446-54. (Pubitemid 41161279)
39. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004;9:422-41. (Pubitemid 39014554)
40. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615-27. (Pubitemid 34177898)
41. Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J, et al. Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. Mol Cancer Ther. 2009;8:2122-30.
42. Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I, et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 2012;72:3290-301.
43. Kang R, Zhang Q, Zeh 3rd HJ, Lotze MT, Tang D. HMGB1 in cancer: good, bad, or both? Clin Cancer Res: Off J Am Assoc Cancer Res. 2013;19:4046-57.
44. Zhang C, Ge S, Hu C, Yang N, Zhang J. MiRNA-218, a new regulator of HMGB1, suppresses cell migration and invasion in non-small cell lung cancer. Acta Biochim Biophys Sin. 2013;45:1055-61.
45. DahlhausM, Schult C, Lange S, Freund M, Junghanss C.MicroRNA 181a influences the expression of HMGB1 and CD4 in acute leukemias. Anticancer Res. 2013;33:445-52.